Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production
A Split-Face, Single-Blind, Study Assessing the Use of a Topical Antioxidant Containing Silymarin With A Series of 1726nm Laser Procedures to Reduce Sebum Production
Austin Institute for Clinical Research
10 participants
Apr 24, 2024
INTERVENTIONAL
Conditions
Summary
This is a split-face, single-blind study assessing the use of an antioxidant serum with a series of acne laser treatments to reduce sebum production in healthy male and female subjects between the ages of 18 and 65 years, inclusive, with Fitzpatrick skin types I-VI.
Eligibility
Inclusion Criteria7
- Healthy male and female subjects aged between 18 and 65 years, inclusive of all Fitzpatrick Skin Types (I-VI)
- Self-perceived "oily skin". Subject must answer "Yes" to the question "Do you have an oily complexion?"
- Mild to moderate acne (2-3) based on IGA
- No known medical conditions that, in the Investigator's opinion may interfere with study participation
- Female subjects of childbearing potential must be on and remain on a study-specified stable form of birth control throughout participation in study (See Section 6.1.1)
- Willingness to cooperate and participate by following study requirements
- Individuals must sign an informed consent and a photography consent
Exclusion Criteria13
- Subjects who meet any of the following criteria will be excluded from the study:
- Subjects that are being treated for cancer or have a history of facial skin cancer on the test areas
- Subjects with sunburn, moderate to pronounced suntan, pronounced asymmetric skin aging, tattoos, scars or other disfiguration, dilated vessels or other conditions on the test area that might influence the test results
- Subjects currently taking certain medications which in the opinion of the Investigators may interfere with the study. This includes but not limited to routine high dosage use of anti-inflammatory drugs (aspirin, ibuprofen, corticosteroids \[steroid nose drops, inhalers and/or eye drops are permitted\]), and immunosuppressive drugs
- Subjects with self-reported, uncontrolled systemic disease which, in the opinion of the Investigator, may hinder either the subject 's ability to perform all responsibilities of the trial or the Investigator's ability to perform assessments
- Females known to be pregnant, nursing or planning to become pregnant
- Subjects participating in other facial clinical studies
- Subjects who have routinely used an alpha-hydroxy-acid (AHA) or a beta-hydroxy-acid (BHA) containing product within two weeks or Retin-A, Retin-A Micro, Renova ,Differin , Avita, Tazorac, or Soriatane within 8 weeks of the study start or have taken Accutane within one year of the study start. Subjects who have used Retinol in the last 8 weeks
- Subjects with history of severe acne flares
- Subjects who have had ablative laser treatments, microneedling, and/or chemical peels or dermabrasion within the last six months
- Subjects who have had non-ablative laser treatments or IPL within the last 3 months
- Subjects with known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs
- Subjects currently using topically applied prescription medications on the face
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.
The AviClear (1726nm) laser is FDA-cleared for use on mild to severe inflammatory acne, with a recommended treatment course comprised of 3 laser procedures each one month apart.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06376110